
Pfizer (PFE), BioNTech (BNTX) Stocks Posititively Reacted to Coronavirus Vaccine Trial
Following the positive news, Pfizer and BioNTech shares managed to jump 5% and 2.2% accordingly on Wednesday. PFE closed with a 3% rise while BTNX lost 4%.
Following the positive news, Pfizer and BioNTech shares managed to jump 5% and 2.2% accordingly on Wednesday. PFE closed with a 3% rise while BTNX lost 4%.
Pfizer suffers a setback in trials targeted at getting Ibrance approved as an early-stage breast cancer therapy. As a result, PFE stock lost around 7% yesterday.
Pfizer (PFE) stock lost 1.94% yesterday but is slightly up today in the pre-market. The company is anticipating to test a COVID-19 vaccine in thousands of people by September.
On Monday, Pfizer announced it had dosed the first participants of the Phase 1/2 clinical trial for the coronavirus vaccine program in the U.S. In general, there will be 360 healthy patients dosed with the vaccine. PFE stock price is rising.
Pfizer (PFE) stock jumped after the company reported an increase in earnings and sales in the first quarter. However, now PFE stock is in the red.
Pfizer had initially planned to enter clinical trials for its coronavirus drug by the end of the year. Now it hopes to start the trials in the third quarter. Pfizer shares price is rising.